Authors also highlight promising data in neurodegenerative diseases, fungal infection, and respiratory diseases including aPAP and COVID-19

Lexington, MA – August 17, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced today that Frontiers in Immunology published a systematic review of LEUKINE® titled, “Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator.  A Drug Before Its Time?” This manuscript chronicles Leukine’s 30-year history in oncology research, including 27 studies that each enrolled 50 or more patients.  Importantly, this ...